Evidence map›Paper›PMID 39971759›Full record

ReviewZeitschrift fur Gerontologie und Geriatrie2025

Management of lung cancer in older adults.

Sven Stieglitz, Valentin Goede, Andreas Schlesinger

Abstract readReview
PubMed Publisher
In one paragraph

Review in Zeitschrift fur Gerontologie und Geriatrie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sven StieglitzDepartment of Internal Medicine I/Pneumology, Cellitinnen-Hospital St. Petrus, Wuppertal, Germany.
Valentin GoedeDepartment of Oncogeriatrics, Center of Geriatric Medicine, Cellitinnen-Hospital St. Marien, Cologne, Germany.
Andreas SchlesingerDepartment of Internal Medicine/Pneumology, Cellitinnen-Hospital St. Marien, Kunibertskloster 11-13, 50668, Cologne, Germany. andreas.schlesinger@cellitinnen.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMore than half of the patients diagnosed with lung cancer are older than 70 years. Good knowledge of the special needs of these patients in diagnosis and treatment is essential for proper management of older adults with lung cancer.

methodsFor this narrative review, an exploratory literature search was conducted using the keywords "lung cancer", "elderly", "geriatric", and "frailty".

resultsCommon diagnostic and therapeutic procedures in older adults with lung cancer are bronchoscopy for histological diagnosis and molecular tissue analyses, staging with computed tomography (CT), positron emission tomography CT (PET-CT) and magnetic resonance imaging (MRI), surgical tumor resection, radiotherapy and systemic therapy including treatment with immune checkpoint or kinase inhibitors. Frailty is common in this group of patients and the geriatric assessment (GA) is suitable for determining the extent of frailty of individual cases. These diagnostic procedures do not pose a high risk even in very old age. Age per se should not preclude curative treatment approaches. Assessment of frailty by GA prior to adjuvant or palliative systemic treatment together with subsequent targeted geriatric interventions improve outcomes of older patients with lung cancer (less treatment toxicity).

conclusionManagement of lung cancer in advanced age requires careful tailoring of diagnostic and therapeutic measures to tumor characteristics, frailty profile and preferences but not the age of individual patients.

Indexed as

Geriatric AssessmentLung NeoplasmsAgedAged, 80 and overFemaleFrail ElderlyFrailtyHumansMaleAgeBronchoscopyFrailtyGeriatric assessmentSystemic treatment

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.